Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| HARECCTR0500049 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to compare two alpha blockers, terazosin and doxazosin GITS, in achieving a successful TWOC after AUR due to BPH, among Chinese males in Hong Kong, and in delaying or avoiding a TURP.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Doxazosin GITS (Cardura XL) | Drug | |||
| Terazosin (Hytrin) | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Successful rate of Trial Without Catheter (TWOC) at phase 1 | At discharge after TWOC (at the end phase one) | |
| Late failure of TWOC of, which is defined as recurrent of AUR or the need of invasive therapy among those who are successful in TWOC in phase 1 | From the end of phase one to eight months after successful TWOC (the end of phase 2) |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of subjects with hypotension or symptoms related to hypotension after administration of treatment drug for TWOC | From the time of treatment drug administration to the end of phase 1 | |
| Peak flow rate (Qmax), voided volume (Vcomp) and post-voided residue volume (PVR) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Chi Wai Cheng, Dr | Department of Surgery, Division of Urology, North District Hospital/ The Chinese University of Hong Kong | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Prince of Wales Hospital | Hong Kong | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| At the end of phase I (discharge after TWOC) and at the end of phase 2 |
| ID | Term |
|---|---|
| D011470 | Prostatic Hyperplasia |
| D016055 | Urinary Retention |
| ID | Term |
|---|---|
| D011469 | Prostatic Diseases |
| D005832 | Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D014555 | Urination Disorders |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
Not provided
Not provided
| ID | Term |
|---|---|
| D017292 | Doxazosin |
| C041226 | Terazosin |
| ID | Term |
|---|---|
| D011224 | Prazosin |
| D011799 | Quinazolines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided